Page 155 WHO - Guidelines on the pharmacological treatment of persisting pain in children with medical illness

73. WHO Expert Committee on the Selection and Use of Essential Medicines. WHO model list
of essential medicines for children: 2nd list (updated) March 2010. Geneva, World Health
Organization, 2010.

74. WHO Expert Committee on the Selection and Use of Essential Medicines. The selection and use of
essential medicines: report of the WHO Expert Committee, 2003 (including the 13th model list
of essential medicines). Geneva, World Health Organization, 2003 (http://whqlibdoc.who.int/trs/
WHO_TRS_920.pdf, accessed 7 September 2011).
75. Mental and behavioural disorders due to psychoactive substance use (F10 F19). In: International
classification of diseases and related health problems. Geneva, World Health Organization, 2007
(Chapter V; http://apps.who.int/classifications/apps/icd/icd10online/, accessed 9 September 2011).

76. Finnegan LP et al. Neonatal abstinence syndrome: assessment and management. Journal of
Addictive Diseases, 1975, 2:141–158.
77. Katz R, Kelly HW, Hsi A. Prospective study on the occurrence of withdrawal in critically ill children
who receive fentanyl by continuous infusion. Critical Care Medicine, 1994, 22:763–767.
78. Tobias JT. Out-patient therapy of iatrogenic opioid dependency following prolonged sedation in
the pediatric intensive care unit. Intensive Care Medicine, 1996, 11:284–287.

79. Robertson RC et al. Evaluation of an opiate-weaning protocol using methadone in pediatric
intensive care unit patients. Pediatric Critical Care Medicine, 2000, 1:119–123.
80. Anand KJ et al. Tolerance and withdrawal from prolonged opioid use in critically ill children.
Pediatrics, 2010, 125:1208–1225.
81. Berde CB, Sethna NF. Analgesics for the treatment of pain in children. New England Journal of
Medicine, 2002, 347:1542.
82. Wong RKS, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases.
Cochrane Database of Systematic Reviews, 2002, (2):CD002068.

83. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database of Systematic
Reviews, 2007, (4):CD005454.
84. Hetrick SE et al. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children
and adolescents. Cochrane Database of Systematic Reviews, 2007, (3):CD004851.
85. The selection and use of essential medicines. Report of the WHO Expert Committee. October 2007
(including the model list of essential medicines for children). Geneva, World Health Organization,
2008 (WHO Technical Report Series, No. 950).
86. Wiffen PJ, McQuay HJ, Moore RA. Carbamazepine for acute and chronic pain in adults. Cochrane
Database of Systematic Reviews, 2005, (3):CD005451.
87. Vedula SS et al. Outcome reporting in industry-sponsored trials of gabapentin for off-label use.
The New England Journal of Medicine, 2009, 361:1963–1971.

88. Bell RF, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane
Database of Systematic Reviews, 2003, (1):CD003351.
89. Challapalli V et al. Systemic administration of local anesthetic agents to relieve neuropathic pain.
Cochrane Database of Systematic Reviews, 2005, (4):CD003345.

> 152